Jessica Zucman-Rossi
Overview
Explore the profile of Jessica Zucman-Rossi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
297
Citations
24241
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lehrich B, Tao J, Liu S, Hirsch T, Yasaka T, Cao C, et al.
JHEP Rep
. 2024 Nov;
6(12):101186.
PMID: 39583094
Background & Aims: Patients with β-catenin (encoded by )-mutated hepatocellular carcinoma (HCC) demonstrate heterogenous responses to first-line immune checkpoint inhibitors (ICIs). Precision-medicine based treatments for this subclass are currently in...
2.
Wege H, Campani C, de Kleine R, Meyer T, Nault J, Pawlik T, et al.
J Hepatol
. 2024 Sep;
PMID: 39289102
In recent years, owing to advances in our understanding of hepatocarcinogenesis, rare primary liver cancers (PLCs), including combined hepatocellular-cholangiocarcinoma, fibrolamellar carcinoma, and hepatic epithelioid hemangioendothelioma have garnered increased attention. In...
3.
La Bella T, Bertin B, Mihaljevic A, Nozi J, Vidal P, Imbeaud S, et al.
Mol Ther Methods Clin Dev
. 2024 Sep;
32(3):101327.
PMID: 39286333
Adeno-associated virus (AAV) is the most widely used vector for gene transfer. A major limitation of capsid engineering is the incomplete understanding of the consequences of multiple amino acid variations...
4.
Lyu X, Sze K, Lee J, Husain A, Tian L, Imbeaud S, et al.
Hepatology
. 2024 Sep;
PMID: 39270063
Background And Aims: HCC is the most common type of primary liver cancer and is a common malignancy worldwide. About half of all new liver cancers worldwide each year occur...
5.
Barre T, Parlati L, Bourliere M, Ramier C, Marcellin F, Protopopescu C, et al.
J Viral Hepat
. 2024 Sep;
31(12):830-846.
PMID: 39252600
Although Hepatitis C virus (HCV) infection can be cured with direct-acting antivirals (DAA), some cured patients face a serious risk of advanced liver damage and early mortality. In order to...
6.
Beulque Y, Kinget L, Roussel E, Mobaraki S, Laenen A, Debruyne P, et al.
Acta Oncol
. 2024 Aug;
63:658-668.
PMID: 39129249
Background And Purpose: This study aims to evaluate neutrophil-to-eosinophil ratio (NER) as a prognostic and/or predictive biomarker in metastatic clear cell renal cell carcinoma (m-ccRCC) treated with nivolumab or ipilimumab/nivolumab....
7.
Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments
Campani C, Imbeaud S, Couchy G, Ziol M, Hirsch T, Rebouissou S, et al.
Gut
. 2024 Jul;
73(11):1870-1882.
PMID: 39054058
Objective: Circulating tumour DNA (ctDNA) is a promising non-invasive biomarker in cancer. We aim to assess the dynamic of ctDNA in patients with hepatocellular carcinoma (HCC). Design: We analysed 772...
8.
Kinget L, Naulaerts S, Govaerts J, Vanmeerbeek I, Sprooten J, Laureano R, et al.
Nat Med
. 2024 Jul;
30(8):2375-2376.
PMID: 39009782
No abstract available.
9.
Kinget L, Naulaerts S, Govaerts J, Vanmeerbeek I, Sprooten J, Laureano R, et al.
Nat Med
. 2024 May;
30(6):1667-1679.
PMID: 38773341
An important challenge in the real-world management of patients with advanced clear-cell renal cell carcinoma (aRCC) is determining who might benefit from immune checkpoint blockade (ICB). Here we performed a...
10.
Roehrig A, Hirsch T, Pire A, Morcrette G, Gupta B, Marcaillou C, et al.
Nat Commun
. 2024 Apr;
15(1):3031.
PMID: 38589411
Hepatoblastomas (HB) display heterogeneous cellular phenotypes that influence the clinical outcome, but the underlying mechanisms are poorly understood. Here, we use a single-cell multiomic strategy to unravel the molecular determinants...